Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Ascendis Pharma A/S

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampAscendis Pharma A/SNeurocrine Biosciences, Inc.
Wednesday, January 1, 2014627400017986000
Thursday, January 1, 2015941500032480000
Friday, January 1, 20161150400068081000
Sunday, January 1, 201713482000169906000
Monday, January 1, 201825057000248932000
Tuesday, January 1, 201948473000354100000
Wednesday, January 1, 202076669000433300000
Friday, January 1, 2021160180000583300000
Saturday, January 1, 2022221227000752700000
Sunday, January 1, 2023264410000887600000
Monday, January 1, 20242845450001007200000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Ascendis Pharma A/S from 2014 to 2023. Over this period, Neurocrine Biosciences has consistently outpaced Ascendis Pharma in SG&A spending, reflecting its aggressive market strategies and expansion efforts. By 2023, Neurocrine's SG&A expenses surged to nearly 890% of their 2014 levels, while Ascendis Pharma's expenses grew by approximately 420%. This stark contrast highlights Neurocrine's commitment to scaling its operations and enhancing its market presence. As these companies continue to evolve, their financial strategies will play a pivotal role in shaping their future trajectories. Investors and industry watchers should keep a close eye on how these expenses translate into market performance and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025